Functional Activation of Mutant p53 by Platinum Analogs in Cisplatin-resistant Cells is Dependent on Phosphorylation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28031409)

Published in Mol Cancer Res on December 28, 2016

Authors

Xiaolei Xie1, Guangan He1, Zahid H Siddik2

Author Affiliations

1: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. zsiddik@mdanderson.org.

Articles cited by this

Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63

Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74

Modes of p53 regulation. Cell (2009) 9.31

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83

Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67

Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem (2001) 5.43

Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96

Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68

The complexity of p53 stabilization and activation. Cell Death Differ (2006) 3.61

MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60

Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46

Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer (2003) 2.88

MDMX: from bench to bedside. J Cell Sci (2007) 2.78

Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55

ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J (2005) 2.29

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood (2006) 2.11

DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem (2003) 2.03

p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03

MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93

MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59

DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol (2005) 1.56

Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene (2005) 1.43

Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33

Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget (2012) 1.24

The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol (2010) 1.23

Mdm2 and MdmX partner to regulate p53. FEBS Lett (2012) 1.22

Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene (2010) 1.13

The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol (2011) 1.13

The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) (2009) 1.12

Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet (2006) 1.09

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res (1999) 1.08

CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer (2004) 1.08

MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol (2002) 1.06

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol (2011) 1.03

Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res (2006) 0.96

HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro Oncol (2010) 0.89

DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiother Oncol (2007) 0.86

Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Cancer Res (1993) 0.85

Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem (1999) 0.85

A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. Medchemcomm (2012) 0.83

Chk2 protects against radiation-induced genomic instability. Radiat Res (2009) 0.78

Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. J Inorg Biochem (1994) 0.77

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene (2016) 0.77